Parkinson Disease
Conditions
Brief summary
The Safety, Tolerability, Pharmacokinetic and Food Effect Study of HEC122505MsOH Tablets in Healthy Subjects
Interventions
DRUGHEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Sponsors
Sunshine Lake Pharma Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects who are willing and are able to provide a written informed consent to participate in the study. 2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout the trial. 3. Subjects aged between 18 and 45 (both inclusive) years old. 4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥18 and ≤28 kg/m2 at screening. 5. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).
Exclusion criteria
1. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP antibodies at screening. 2. Patients with the following diseases of clinical significance, including but not limited to those with gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases. 3. nown allergic reactions or hypersensitivity to any excipient of the drug formulation(s)， anaphylaxis physique. 4. Use of any prescription or non-prescription medications within 14 days prior to initial dosing，Use of any drugs that inhibit or induce liver metabolism within 28 days before the first dose, or use of any of the following drugs within 28 days before the first dose: monoamine oxidase inhibitors, opioids, serotonergic drugs, sympathetic nerves Drugs, breast cancer resistance protein substrates, dopaminergic antagonists, etc. 5. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing. 6. Positive results from urine drug screen test. 7. History of alcoholism or drink regularly within 3 months prior to the study (defined as Alcohol consumption of \> 21 units/week), or positive results from alcohol breath test. 8. Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug, or inability to refrain from smoking during the course of the study. 9. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing. 10. Subjects who plan to receive or have had organ transplants. 11. Females who are lactating/breastfeeding, or positive result from pregnancy test for women of child-bearing potential. 12. Subjects who participated in another clinical trial within 3 months prior to initial dosing. 13. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Adverse Events (AEs) | Part 1：up to 6 days; Part 2: up to 13 days. | To investigate the safety and tolerability of HEC122505MsOH by assessment of AEs (non-serious and serious) following administration of oral HEC122505MsOH tablets |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | up to 120 hours | Maximum Plasma Concentration(Cmax) |
| AUC | up to 120 hours | Area Under the Curve(AUC) |
| Tmax Tmax | up to 120 hours | Maximum Peak Time(Tmax) |
| t½ | up to 120 hours | Elimination Half-life(t½) |
| Vz/F | up to 120 hours | Apparent Volume of Distribution(Vz/F) |
| Kel | up to 120 hours | Elimination Rate Constant(Kel) |
| MRT | up to 120 hours | Mean Residence Time(MRT) |
| CL/F | up to 120 hours | Apparent Clearance(CL/F) |
Other
| Measure | Time frame | Description |
|---|---|---|
| MAO-B | up to 120 hours | Monoamine Oxidase B（MAO-B） |
| MAO-A | up to 120 hours | Monoamine Oxidase A（MAO-A） |
Countries
China
Outcome results
None listed